Kane Biotech adds U.S. distributors for revyve products

Executive Summary

• Kane Biotech Inc. has entered into non-exclusive distribution and sales agreements for its revyve antimicrobial wound gel product line with two new U.S. partners: Patient Care Medical and Life Biologics.
• The agreements expand the company's commercial presence in targeted geographic markets and sales channels, with initial shipments expected in the near term.
• The revyve product line holds U.S. FDA 510(k) clearance and Health Canada approval.

Key Details

• Partnership 1: Life Biologics (Lakewood, N.J.) will distribute the products nationally within the advanced wound care sector.
• Partnership 2: Patient Care Medical (Austin, Tex.) will distribute the products within Louisiana, Mississippi, and the Gulf Coast, specializing in in-hospital and mobile wound care facilities.
• Product: revyve antimicrobial wound gel and revyve antimicrobial wound gel spray.
• Regulatory Status: The products are cleared by the U.S. FDA (510(k)) and approved by Health Canada.
• Commercial Status: Preparations are underway for initial shipments in the near term.

Notable Quotes

• "Expanding our U.S. distribution network remains a key priority for the company. These agreements enhance our access to selected U.S. markets and support our near-term commercialization objectives." — Dr. Robert Huizinga, Interim Chief Executive Officer